Latest news with #Resilience
NZ Herald
8 hours ago
- Science
- NZ Herald
Do you see craters or bumps on the Moon's surface?
A picture of the Moon's south pole was taken in May by Resilience, a robotic lander operated by the Japanese company Ispace that probably crashed on the lunar surface last week. Some people see bumps, but others see craters. What you're seeing is known as the crater illusion, or sometimes
Yahoo
13 hours ago
- Business
- Yahoo
Resilience Provides Customers With Update on CDMO Business Strategy and Manufacturing Footprint
Will Focus on High-Growth Segments of Advanced Therapeutics Manufacturing and Consolidate Operations Legal Proceedings to Wind Down Underutilized Sites Do Not Include Resilience or Its Go-Forward Manufacturing Operations Anchored by Cincinnati Facility Existing Institutional Investors Provided $250 Million in Bridge Financing to Support Transformation SAN DIEGO & CINCINNATI, June 09, 2025--(BUSINESS WIRE)--National Resilience ("Resilience"), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and financing in a letter to its customers. The full letter follows: Dear Resilience Customers, Since our founding in 2020, Resilience has focused on improving the pharmaceutical supply chain and providing manufacturers of complex, advanced medicines the ability to produce drugs at scale and on shore. During this time, we have been consistently evolving to capture the market opportunities that match our resources and capabilities with our customers' priorities. Most recently, we have determined that the best use of our expertise, resources, and talent is to focus on high-growth segments to advance cell-based medicines, primarily biologics, and aseptic drug product operations. It has also become clear that our capacity expansion has outpaced industry demand. As a result, we have been consolidating our operations to pursue a tailored business strategy with a streamlined footprint. To advance our transformation while continuing to serve our customers with excellence, it was determined that sites not being fully utilized needed to be wound down in a prompt and efficient manner through legal proceedings commenced by a leaseholder affiliate. Importantly, Resilience and our go-forward manufacturing operations, anchored by our Cincinnati facility, are fully operational and not included in those proceedings. Of note, our transformation has the support of our shareholders, with a consortium of existing institutional investors having provided $250 million in bridge financing to support the consolidation of our manufacturing footprint. We are also pursuing additional debt financing to fuel our longer-term growth plans. Resilience is on track to become a leaner, stronger enterprise, with the right focus and the right footprint to serve you even better in the future. Thank you for your continued partnership during our transformation journey. Sincerely, William S. Marth, RPh., MBAPresident & Chief Executive Officer About Resilience Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably. The company is building a streamlined, high-performance network designed to meet the evolving needs of clinical and commercial-stage innovators. For more information, visit and follow us on social media: Resilience on LinkedIn. View source version on Contacts Media: Kekst CNCResilienceMedia@ Catherine HanleyVice President, Corporate
Business Wire
13 hours ago
- Business
- Business Wire
Resilience Provides Customers With Update on CDMO Business Strategy and Manufacturing Footprint
SAN DIEGO & CINCINNATI--(BUSINESS WIRE)--National Resilience ('Resilience'), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today provided an update on its CDMO business strategy and financing in a letter to its customers. The full letter follows: Dear Resilience Customers, Since our founding in 2020, Resilience has focused on improving the pharmaceutical supply chain and providing manufacturers of complex, advanced medicines the ability to produce drugs at scale and on shore. During this time, we have been consistently evolving to capture the market opportunities that match our resources and capabilities with our customers' priorities. Most recently, we have determined that the best use of our expertise, resources, and talent is to focus on high-growth segments to advance cell-based medicines, primarily biologics, and aseptic drug product operations. It has also become clear that our capacity expansion has outpaced industry demand. As a result, we have been consolidating our operations to pursue a tailored business strategy with a streamlined footprint. To advance our transformation while continuing to serve our customers with excellence, it was determined that sites not being fully utilized needed to be wound down in a prompt and efficient manner through legal proceedings commenced by a leaseholder affiliate. Importantly, Resilience and our go-forward manufacturing operations, anchored by our Cincinnati facility, are fully operational and not included in those proceedings. Of note, our transformation has the support of our shareholders, with a consortium of existing institutional investors having provided $250 million in bridge financing to support the consolidation of our manufacturing footprint. We are also pursuing additional debt financing to fuel our longer-term growth plans. Resilience is on track to become a leaner, stronger enterprise, with the right focus and the right footprint to serve you even better in the future. Thank you for your continued partnership during our transformation journey. Sincerely, William S. Marth, RPh., MBA President & Chief Executive Officer About Resilience Resilience is a North American contract development and manufacturing organization (CDMO) focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, Resilience partners with leading biopharma companies to bring complex medicines to market faster and more reliably. The company is building a streamlined, high-performance network designed to meet the evolving needs of clinical and commercial-stage innovators. For more information, visit and follow us on social media: Resilience on LinkedIn.
Mail & Guardian
18 hours ago
- General
- Mail & Guardian
Call for nominations: Power of Women 2025
This year marks the 19th anniversary of the Mail & Guardian's annual flagship event, Power of Women, where the immense contributions made by South African women are recognised and celebrated. This year's theme, 'I n the Spirit of Women20: Celebrating Women Who Turn the Impossible into Unstoppable ', will pay tribute to the women who challenge limitations, shift narratives and lead with a purpose. We invite you to nominate powerful women from all sectors and communities. Whether they work in science, social justice, the arts, education, entrepreneurship or beyond, this initiative celebrates stories of resilience and determination that often go unseen. This is your opportunity to nominate individuals whose work has a lasting effect, drives progress and inspires future generations. The winners will be announced on 28 August, the month in which the Mail & Guardian celebrates Women's Month and when the nation observes National Women's Day. The closing date for nominations is 20 July 2025. Please submit your nomination by clicking For more information about the Power of Women, visit the website
Yahoo
2 days ago
- Science
- Yahoo
Japanese Lunar Lander Crashes In Second Failed Mission
A private Japanese lunar lander crashed during an attempted touchdown on the moon Friday. This marks the second failed mission for the Tokyo-based global lunar exploration company, ispace. The lander, named Resilience, lost communication less than two minutes before its scheduled landing in Mare Frigoris, a flat, crater-filled region on the moon's northern near side. A preliminary analysis indicated the laser system for measuring altitude malfunctioned, causing the lander to descend too fast. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' ispace said in a statement. 'This is the second time that we were not able to land. So we really have to take it very seriously,' CEO and founder Takeshi Hakamada told reporters, per Associated Press. He apologized to contributors and added that the mission was 'merely a stepping stone' to a larger lander planned for 2027 with NASA involvement. 'Engineers did everything they possibly could' to ensure success, he said minutes before the attempted landing. The 7.5-foot Resilience, launched in January from Florida on a SpaceX rocket, carried an 11-pound, four-wheeled rover named Tenacious, built by ispace's Luxembourg subsidiary. The rover, equipped with a high-definition camera and a shovel for NASA to collect lunar soil, was designed to operate for two weeks during the moon's daylight period. It also carried a toy-size Swedish-style red cottage, dubbed Moonhouse by artist Mikael Genberg, for placement on the lunar surface. The mission's $16 million payload included scientific instruments from Japanese firms and a Taiwanese university. The failure follows ispace's first lunar crash in 2023, caused by inaccurate altitude readings. 'Truly diverse scenarios were possible, including issues with the propulsion system, software or hardware, especially with sensors,' Chief Technology Officer Ryo Ujiie said at a press conference. Jeremy Fix, chief engineer for ispace's U.S. subsidiary, noted last month that the company, with a mission cost less than the first's $100 million, lacks 'infinite funds' and cannot afford repeated failures. 'We're not facing any immediate financial deterioration or distress because of the event,' CFO Jumpei Nozaki said, citing investor support. However, space shares faced heavy sell orders and were poised for a 29% drop. As of Thursday, their market capitalization was over 110 billion yen ($766 million). The crash marks another setback in the commercial lunar race, which began in 2019. U.S. firms Firefly Aerospace and Intuitive Machines achieved successful landings in March, though Intuitive's lander toppled in a crater. Japan's space agency, JAXA, landed its SLIM probe last year, joining Russia, the U.S., China, and India as the only nations with successful robotic lunar landings. 'Expectations for ispace have not faded,' Japanese Prime Minister Shigeru Ishiba posted on X, reported Reuters. Ispace remains committed to NASA's Artemis program, with plans for a third mission in 2027. 'NASA increasingly needs private companies to improve cost efficiency for key missions with limited budgets,' Hakamada said, referencing proposed U.S. budget cuts. Two U.S. companies, Blue Origin and Astrobotic Technology, aim for moon landings by year's end following Astrobotic's 2024 failure.
